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Pauci-immune glomerulonephritis: the ANCA-negative side
of the coin
Anti-neutrophil cytoplasmic antibodies (ANCAs) were
first described as ‘tools for diagnosis and markers of dis-
ease activity’ in a set of small vessel vasculitides charac-
terized by frequent renal injury.1 Since then, a first
generation of seminal studies further enforced the clini-
cal and pathogenic relevance of ANCA for granulo-
matosis with polyangiitis (GPA), eosinophilic
granulomatosis with polyangiitis (EGPA), microscopic
polyangiitis (MPA) and renal-limited pauci-immune
vasculitis, which were thus grouped as ‘ANCA-
associated vasculitides (AAVs)’.2–4 At the same time,
diagnostic advances occurred with the introduction of
more accurate quantitative methods (such as enzyme-
linked or chemiluminescence assays) for the specific
recognition of anti-myeloperoxidase (MPO) and anti-
proteinase-3 (PR3) antibodies, besides conventional
immunofluorescence. Recent genetic studies5 pointed
out that AAV subsets can be distinguished not only by
clinical diagnosis and organ involvement, but also by
ANCA status (i.e. a specific ANCA type was associated
with a different genetic background), paving the way to
a novel serological classification of AAV. Several
additional studies confirm the usefulness of this ANCA-
centred approach at a clinical level and support the
contention that some pathogenic mechanisms may vary
depending on presence and type of ANCAs. For exam-
ple, ANCA-positive patients with EGPA have more
prominent vasculitic manifestations.6 In addition, anti-
PR3-positive patients respond better to rituximab (RTX)
than to cyclophosphamide,7 but have a higher cardio-
vascular risk8 and are more likely to experience relapse
after renal transplant when compared to MPO-positive
patients.9 Finally, the ANCA titre could predict disease
flares and indicate the optimal timing for RTX adminis-
tration10 (NCT01731561, MAINRITSAN-2 trial).
However, while a classification based upon an anti-
MPO versus anti-PR3 dichotomy seems promising for
an accurate clinical-pathogenic stratification of
patients, the smaller, but clinically significant subset of
ANCA-negative patients remains in an indefinite
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Figure 1 Possible logical relations between anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) and
pauci-immune glomerulonephritis (PIGN). ANCA+ AAV (blue elipses) and AAV (light blue elipses) are shown. The area within the
AAV set but outside the ANCA+ set represent ANCA-negative AAV patients. PIGN (green elipses) has a higher percentage of ANCA-
negative patients. Further research on ANCA-negative patients with PIGN might determine whether (Panel a) or not (Panel b) all
these patients belong to the AAV spectrum.
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Limbo. Infact, ANCA-negative patients are character-
ized by the lack of specific clinical manifestations and
are more frequently described (excluding EGPA) in
nephrology series, since they often present with iso-
lated pauci-immune glomerulonephritis (PIGN) with-
out extra-renal manifestations of AAVs.11–14 Despite
this finding, the prognostic relevance of ANCA status
in patients with crescentic PIGN is controversial.11–14
The article by Sharma and colleagues,15 in this issue of
the IJRD, sheds light on this topic by investigating a
monocentric cohort of 84 subjects with PIGN, includ-
ing 33 ANCA-negative patients. The authors report that
a significantly lower fraction of ANCA-negative
patients experience an improvement in renal function
or become dialysis-independent after therapy, despite
lower Birmingham vasculitis activity scores at presenta-
tion. Sharma et al. also point out that ANCA-negative
patients have fewer extra-renal manifestations despite a
more severe active glomerular injury in terms of pres-
ence of cellular crescents, and more advanced intersti-
tial fibrosis. Unfortunately, the authors stratified their
sample only on the basis of immunofluorescence
results, without taking into account the results of the
anti-MPO and anti-PR3 enzyme-linked immunosor-
bent assays.
Taken together, these data suggest that ANCA-negative
patients do not simply lack a diagnostic marker, but
may more correctly lack a definite diagnosis. Specific
and still unknown pathogenic mechanisms could be
active in this group of patients and explain the pheno-
type discrepancy with anti-MPO/PR3-positive patients.
For example, other autoantibodies have been previously
associated with ANCA-negative patients, and it is
possible that some of them will not exert an ANCA-like
biological behavior. Consequently, the so-called
ANCA-negative subset may be more heterogeneous than
previously thought and mistakenly include pathologies
that do not even belong to the AAV spectrum (Fig. 1).
We believe that clarification of this point is crucial, and
further studies are needed to address this issue.
In conclusion, ANCA status distinguishes between
disease subsets both in AAV and PIGN. Recent data sug-
gest that genetic predisposition, clinical phenotype, his-
tology, response to therapy and possibly prognosis
differ according to ANCA status. In the future, we
should try to overcome the current definition of one
subset of patients based on negation (i.e., ANCA-nega-
tive, without extra-renal manifestations). Further
research should aim to clarify whether all patients with
ANCA-negative PIGN should be included within the
AAV spectrum and seek novel auto-antibodies. Finally,
increased efforts are needed to identify more homoge-
nous subsets of ANCA-negative PIGN, with the aim to
improve knowledge of pathogenesis, hopefully paving
the way to better therapies and outcomes.
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